|Articles|August 6, 2014

Risk and Innovation in Biopharma: A CEO’s Perspective

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.

Click here for the article.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Risk and Innovation in Biopharma: A CEO’s Perspective

Related Content

Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering

GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.

Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner

Transitioning from BGB to BGBx: Q&A with David Coman

Right–to-Try Does Not Undermine Clinical Trials

Trending on PharmExec

Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio

Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata

Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner

Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration

Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg